Investigation of variations of pyrazinamide resistance and gene Xpert-based molecular typing in tuberculosis patients

Riffat Naseem; Muhammad Israr; Shahzaib Khan; Muhammad Aarab; Muhammad Yousuf; Hafiz Zia Ullah Abid

doi:10.53730/ijhs.v7nS1.14599

Authors

Riffat Naseem
rnemail1985@gmail.com
Department of Life Sciences, Abasyn University Peshawar
Muhammad Israr Department of Life Sciences, Abasyn University Peshawar
Shahzaib Khan Department of Microbiology, Abbottabad University of Science and Technology
Muhammad Aarab Scientific Officer, Department of Quality Control Laboratory (Biological), NIH Islamabad Pakistan
Muhammad Yousuf Institute of Microbiology, Government College University Faisalabad
Hafiz Zia Ullah Abid Department institute of Industrial of Biotechnology, Government College University Faisalabad

Keywords:

Mycobacterium tuberculosis, Gene Xpert assay, Pleural tuberculosis, pyrazinamide resistance

Abstract

The morbidity, death, and medication resistance caused by Mycobacterium tuberculosis are global health concern. The Gene Xpert is employed to diagnose TB early and find pyrazinamide (PYR) resistance at the same time. Our goal was to examine the clinical TB situation at Faisalabad's tertiary care institutions and to use Gene Xpert to determine the prevalence of TB and the drug resistance pattern. In this research, 135 samples from probable TB patients were included, and Gene Xpert identified 127 samples as positive. The gender, age group (50 years), sample type (sputum and pleural), and number of M. tuberculosis by ct value (cycle threshold) were all taken into consideration when categorizing the samples. The findings of the current investigation revealed a significant positive frequency of TB in male patients and in the 31-50 years age ranges. Patients with TB had a high prevalence of M. tuberculosis in the low and medium categories. 16 of the 127 TB patients who tested positive for the disease had pyrazinamide resistance. Our study concluded that Gene Xpert is a useful method for quickly diagnosing and treating TB since it can quickly detect M. tuberculosis and pyrazinamide resistance.

Downloads

Download data is not yet available.

References

Atashi S, Izadi B, Jalilian S, Madani SH, Farahani A and Mohajeri P (2017). Evaluation of GeneXpert MTB/PYR for determination of pyrampicin resistance among new tuberculosis cases in west and northwest Iran. New Microbes New Infect, 19(1): 117-120.

Dunn JJ, Starke JR and Revell PA (2016). Laboratory diagnosis of mycobacterium tuberculosis infection and disease in children. Clin Microbiol Infect, 54(6): 1434- 1441.

Elbrolosy AM, El Helbawy RH, Mansour OM and Latif RA (2021). Diagnostic utility of GeneXpert MTB/PYR assay versus conventional methods for diagnosis of pulmonary and extra-pulmonary tuberculosis. BMC Microbiol, 21(1): 1-10.

Global tuberculosis report (2017). Geneva: World Health Organization, pp.1-262.

Global tuberculosis report (2021). Geneva: World Health Organization, pp.1-57.

Goroh MMD, Rajahram GS, Avoi R, Van Den Boogaard CHA, William T, Ralph AP and Lowbridge C (2020). Epidemiology of tuberculosis in Sabah, Malaysia, 2012-2018. Infect. Dis. Poverty, 9(1): 1-11.

Hefzy EM, Ahmed MI, Ahmed AM and Ali DY (2021). Utility of GeneXpert MTB/PYR assay for the diagnosis of pulmonary and extra-pulmonary tuberculosis, A report from Egypt. Nov. Res. Microbiol. J., 5(1): 1146- 1161.

Hernández-Garduño E, Cook V, Kunimoto D, Elwood RK, Black WA and FitzGerald JM (2004). Transmission of tuberculosis from smear negative patients: A molecular epidemiology study. Thorax, 59(4): 286-290.

Kabir S, Tanveer Hossain Parash M, Emran NA, Tofazzal Hossain ABM and Shimmi SC (2021). Diagnostic challenges and Gene-Xpert utility in detecting Mycobacterium tuberculosis among suspected cases of Pulmonary tuberculosis. PLoS One, 16(5): 1-16.

Liang Q, Pang Y, Yang Y, Li H, Guo C, Yang X and Chen X (2019). An improved algorithm for rapid diagnosis of pleural tuberculosis from pleural effusion by combined testing with GeneXpert MTB/PYR and an anti-LAM antibody-based assay. BMC Infect. Dis, 19(1): 1-8.

Linguissi LSG, Vouvoungui CJ, Poulain P, Essassa GB, Kwedi S and Ntoumi F (2015). Diagnosis of smearnegative pulmonary tuberculosis based on clinical signs in the Republic of Congo Infectious Diseases. BMC Res. Notes, 8(1): 1-7.

Macías A, Sánchez-Montalvá A, Salvador F, Villar A, Tórtola T, Saborit N and Molina I (2019). Epidemiology and diagnosis of pleural tuberculosis in a low incidence country with high rate of immigrant population: A retrospective study. Int. J. Infec. Dis., 78(1): 34-38.

MacLean E, Kohli M, Weber SF, Suresh A, Schumacher SG, Denkinger CM and Pai M (2020). Advances in molecular diagnosis of tuberculosis. J. Clin. Microbiol., 58(10): 1-13.

Masenga SK, Mubila H and Hamooya BM (2017). pyrampicin resistance in Mycobacterium tuberculosis patients using GeneXpert at Livingstone Central Hospital for the year 2015: A cross sectional explorative study. BMC Infect. Dis., 17(1): 1-4.

Matabane MMZ, Ismail F, Strydom KA, Onwuegbuna O, Omar SV and Ismail N (2015). Performance evaluation of three commercial molecular assays for the detection of Mycobacterium tuberculosis from clinical specimens in a high TB-HIV-burden setting. BMC Infect. Dis., 15(1): 508.

Mechal Y, Benaissa E, El Mrimar N, Benlahlou Y, Bssaibis F, Zegmout A, Chadli M, Malik YS, Touil, N, Abid A, Maleb A and Elouennass M (2019). Evaluation of GeneXpert MTB/PYR system performances in the diagnosis of extra-pulmonary tuberculosis. BMC Infect. Dis., 19(1): 1-8.

Metcalf T, Soria J, Montano SM, Ticona E, Evans CA, Huaroto L, Kasper M, Ramos ES, Mori N, Jittamala, P, Chotivanich K, Chavez IF, Singhasivanon P, Pukrittayakamee S and Zunt P (2018). Evaluation of the GeneXpert MTB/PYR in patients with presumptive tuberculous meningitis. PLoS One, 13(6): 1-15.

Mulu W, Abera B, Yimer M, Hailu T, Ayele H and Abate D (2017). Pyrampicin-resistance pattern of Mycobacterium tuberculosis and associated factors among presumptive tuberculosis patients referred to Debre Markos Referral Hospital, Ethiopia: A crosssectional study. BMC Res. Notes, 10(1): 1-8.

Mustafa T, Wergel I, Baba K, Pathak S, Hoosen AA and Dyrhol-Riise AM (2020). Mycobacterial antigens in pleural fluid mononuclear cells to diagnose pleural tuberculosis in HIV co-infected patients. BMC Infect. Dis, 20(1): 1-13.

Phillips, J.A. 2018. Global Tuberculosis report. World Health Organization, Geneva, Switzerland, pp.1-277.

Pienaar E, Linderman JJ and Kirschner DE (2018). Emergence and selection of isoniazid and PYRampin resistance in tuberculosis granulomas. PLoS One, 13(5): 1-29.

Rahman H, Khan SU, Khan MA, Qasim M, Jabbar A, Noor S, Khan Z, Khan TA, Hussain M, Muhammad N and Ali N (2017). Molecular detection of PYRampicin resistance by GeneXpert assay among treated and untreated pulmonary tuberculosis patients from Khyber Pakhtunkhwa, Pakistan. J. Glob. Antimicrob. Resist, 9(1): 118-120.

Shaw JA, Diacon AH and Koegelenberg CFN (2019). Tuberculous pleural effusion. Respirology, 24(10): 962-971.

Sinshaw W, Kebede A, Bitew A, Tesfaye E, Tadesse M, Mehamed Z, Yenew B, Amare M, Dagne B, Diriba G, Alemu A, Getahun M, Fikadu D, Desta K and Tola HH (2019). Prevalence of tuberculosis, multidrug resistant tuberculosis and associated risk factors among smear negative presumptive pulmonary tuberculosis patients in Addis Ababa, Ethiopia. BMC Infect. Dis, 19(1): 1- 15.

Smiljic S, Radovc B, Ilic A, Trajkovic G, Savic S, Milanovic Z and Mijovic M (2019). Differences and similarities between the symptoms and clinical signs in patients with pulmonary tuberculosis and pneumonia. Vojnosanit. Pregl, 76(2): 192-201.

Silva DR, Rabahi MF, Sant'Anna CC, Silva-Junior JLRD, Capone D, Bombarda S, Miranda SS, Rocha JLD, Dalcolmo MMP, Rick MF, Santos AP, Dalcin PTR, Galvão TS and Mello FCQ (2021). Diagnosis of tuberculosis: A consensus statement from the Brazilian Thoracic Association. J.. Bras Pneumol., 47(2): 1-13.

Theron G, Peter J, Calligaro G, Meldau R, Hanrahan C.H. Khalfey C, Matinyenya B, Muchinga T, Smith L, Pandie S, Lenders L, Patel V, Mayosi BM and Dheda K (2014). Determinants of PCR performance (Xpert MTB/PYR), including bacterial load and inhibition for TB diagnosis using specimens from different body compartments. Sci. Rep, 4(11): 1-10.

Tostmann A, Kik SV, Kalisvaart NA, Sebek MM, Verver,S., Boeree MJ and Soolingen DV (2008). Tuberculosis transmission by patients with smearnegative pulmonary tuberculosis in a large cohort in the Netherlands. Clin. Infect. Dis., 47(9): 1135-1142.

Ullah W, A Wali, MU Haq, A Yaqoob, R Fatima and GM Khan (2021). Public-private mix models of tuberculosis care in Pakistan: A high-burden country perspective. Front. Public Heal, 9(1): 1-11. Vilcheze C and Jacobs WR (2015). Resistance to isoniazid and ethionamide in Mycobacterium tuberculosis: Genes, mutations and causalities. Mol. Genet. Mycobact., 2(4): 431-453.

WHO (2013). Automated Real-Time Nucleic Acid Amplification Technology for Rapid and Simultaneous Detection of Tuberculosis and PYRampicin Resistance: Xpert MTB/PYR Assay for the Diagnosis of Pulmonary and Extra-pulmonary TB in Adults and Children: Policy update. World Heal. Organ. pp.1-79.

WHO (2021) Regional Office for the Eastern Mediterranean (EMRO). Pakistan, programme areas, tuberculosis. http://www.emro.who.int/pak/programmes/stop tuberculosis. html.

Zhang X, Andersen AB, Lillebaek T, Kamper-Jørgensen Z, Thomsen VO, Ladefoged K, Marrs CF, Zhang L and Yang Z (2011). Effect of sex, age and race on the clinical presentation of tuberculosis: A 15-year population-based study. Am. J. Trop. Med. Hyg., 85(2): 285-290.

Zong K, Luo C, Zhou H, Jiang Y and Li S (2019). Xpert MTB/PYR assay for the diagnosis of PYRampicin resistance in different regions: A meta-analysis. BMC Microbiol. 19(1): 1-21.